GlobeNewsWire · IMRX · November 12, 2026

Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer

Get the app for more

Explore stock news, insights and company research.